Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Pediatric Primary IgA Nephropathy
jRCT2031250555Recruiting
- Sponsor
- Novartis
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Open-label trial of Iptacopan in IgA nephropathy (IgAN) (2 cohorts), sponsored by Novartis. Started Apr 2026; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2031250555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250555.